Company profile for Enlaza Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.Operator of a biotechnology research ...
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.Operator of a biotechnology research company intended to offer protein therapeutics. The company enables biological drugs that are engineered to become warheads with the capacity to irreversibly lock to disease-related targets.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
11099 North Torrey Pines Road, Ste 280 La Jolla, California, 92037
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/business/vertex-enlaza-declare-war-on-autoimmune-disease-in-potential-2b-pact

BIOSPACE
03 Sep 2025

https://www.businesswire.com/news/home/20240613497600/en

BUSINESSWIRE
18 Jun 2024
Enlaza Therapeutics secures $100m in Series A funding
Enlaza Therapeutics secures $100m in Series A funding

01 May 2024

// PHARMACEUTICAL TECHNOLOGY

https://www.pharmaceutical-technology.com/news/enlaza-series-a-funding/

PHARMACEUTICAL TECHNOLOGY
01 May 2024

https://www.biopharmadive.com/news/enlaza-therapeutics-series-a-covalent-biologics/714649/

Gwendolyn Wu BIOPHARMADIVE
30 Apr 2024

https://www.businesswire.com/news/home/20240430950707/en

BUSINESSWIRE
30 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty